Lilly's Solanezumab Slows Down Alzheimer's Progression

Solanezumab, an experimental Eli Lilly medication for Alzheimer's disease, slowed the rate of cognitive decline and memory loss by approximately 30% among patients in early stages of the disease. MNT

No comments:

Post a Comment